Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Specific Aim 1: As part of a within-subject, two-days, study design, to determine whether
acute calcitriol (vs. placebo) pre-treatment is associated with greater amphetamine
(Amp)-induced dopamine (DA) release in the caudate, putamen, ventral striatum (VST), and
substantia nigra / ventral tegmental area (SN/VTA) of healthy human subjects.
Specific Aim 2: To determine whether acute calcitriol (vs. placebo) pre-treatment is
associated with better performance on a test of attention (e.g., the continuous Performance
Task or CPT-AX), after treatment with amphetamine. Hypothesis: Investigators hypothesize that
Subjects pre-treated with calcitriol will have faster reaction times/higher accuracy on the
CPT-AX vs. subjects pre-treated with placebo, after treatment with amphetamine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
Brain & Behavior Research Foundation
Treatments:
Amphetamine Calcitriol Central Nervous System Stimulants Dextroamphetamine Ergocalciferols Raclopride Vitamin D Vitamins